NASDAQ · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) · SMALL CAP
Champions Oncology, Inc. CSBR
16 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
Revenue · FY2025
$59.4M
▲ 4.4% vs FY2024
EPS · FY25
$-0.08
Dividend / sh · FY25
—
Payout · FY25
—
ROE · FY25
-30.5%
Net margin · FY25
-2.0%
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 59.4M
Revenue, FY2025 · full 16-year series below
Revenue
Net income
The company lost 2 cents on every revenue dollar this year.
Per share
USD -0.08
Diluted EPS, FY2025
EPS
The company pays no cash dividend.
Profitability
-30.5%
Return on equity, FY2025
ROE
Operating margin-1.9%
Net margin-2.0%
Return on assets-4.0%
Each USD of equity lost 30 cents this year.
Returned to shareholders
—
returned in FY2025 · dividends + net buybacks
Dividends paid—
Net buybacks—
Share of profit—
Consecutive raises—
Growth
+7.7% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
+3.3%
+7.7%
+18.2%
+15.5%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
0.01B
Shares outstanding, FY2025
Change, 5 years+3.5%
Change, 10 years+59.5%
The share count grew 4% in five years — the same company, cut into more, smaller slices.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 27.0M
total assets, end of FY2025
Total assetsUSD 27.0M
EquityUSD 3.9M
CashUSD 4.9M
Current ratio0.96×
Equity funds 15% of total assets.
History
16 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
Revenue $B
0.1
0.1
0.1
0.1
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
Operating income $B
−0.0
0.0
−0.0
−0.0
0.0
0.0
−0.0
0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
EBITDA $B
0.0
0.0
−0.0
−0.0
0.0
0.0
−0.0
0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
Income tax $B
0.0
−0.0
−0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
−0.0
0.0
Net income $B
−0.0
0.0
−0.0
−0.0
0.0
0.0
−0.0
0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
EPS, diluted $
−0.08
0.33
−0.54
−0.39
0.04
0.02
−0.18
0.01
−0.13
−0.64
−1.20
−2.20
−0.11
−0.12
−0.19
−0.11
Dividend / sh $
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
ROE %
−30.5
503.0
−532.5
−77.7
6.6
5.8
−57.8
12.0
−732.5
−2158.0
−251.8
−233.5
·
·
·
−476.4
Shares out B
0.01
0.01
0.01
0.01
0.01
0.01
0.01
0.01
0.01
0.01
0.01
0.01
0.07
0.04
0.03
0.03
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
47 of 47
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed